@article{8728051,
  abstract     = {{Synthetic cannabinoid receptor agonists (SCRAs) remain a prolific class of new psychoactive substances (NPS) and continue to expand rapidly. Despite the recent identification of hydroxybenzotriazole (HOBt) containing SCRAs in synthetic cannabis samples, there is currently no information regarding the pharmacological profile of these NPS with respect to human CB1 and CB2 receptors. In the current study, a series consisting of seven HOBt indole-, indazole-, and 7-azaindole-carboxylates bearing a range of N-alkyl substituents were synthesized and pharmacologically evaluated. Competitive binding assays at CB1 and CB2 demonstrated that all analogues except a 2-methyl-substituted derivative had low affinity for CB1 (K-i = 3.80-43.7 mu M) and CB2 (K-i = 2.75-18.2 mu M). A fluorometric functional assay revealed that 2-methylindole- and indole-derived HOBt carboxylates were potent and efficacious agonists of CB1 (EC50 = 12.0 and 63.7 nM; E-max = 118 and 120%) and CB2 (EC50 = 10.9 and 321 nM; E-max = 91 and 126%). All other analogues incorporating indazole and 7-azaindole cores and bearing a range of N1-substituents showed relatively low potency for CB1 and CB2. Additionally, a reporter assay monitoring beta-arrestin 2 (beta arr2) recruitment to the receptor revealed that the 2-methylindole example was the most potent and efficacious at CB1 (EC50 = 131 nM; E-max = 724%) and the most potent at CB2 (EC50 = 38.2 nM; E-max = 51%). As with the membrane potential assay, the indazole and other indole HOBt carboxylates were considerably less potent at both receptors, and analogues comprising a 7-azaindole core showed little activity. Taken together, these data suggest that NNL-3 demonstrates little CB1 receptor activity and is unlikely to be psychoactive in humans. NNL-3 is likely an unintended SCRA manufacturing byproduct. However, the synthesis of NNL-3 analogues proved simple and general, and some of these showed potent cannabimetic profiles in vitro, indicating that HOBt esters of this type may represent an emerging class of SCRA NPS.}},
  author       = {{Ametovski, Adam and Cairns, Elizabeth A. and Grafinger, Katharina Elisabeth and Cannaert, Annelies and Deventer, Marie and Chen, Shuli and Wu, Xinyi and Shepperson, Caitlin E. and Lai, Felcia and Ellison, Ross and Gerona, Roy and Blakey, Karen and Kevin, Richard and McGregor, Iain S. and Hibbs, David E. and Glass, Michelle and Stove, Christophe and Auwaerter, Volker and Banister, Samuel D.}},
  issn         = {{1948-7193}},
  journal      = {{ACS CHEMICAL NEUROSCIENCE}},
  keywords     = {{HERBAL MIXTURES UPDATE,PHARMACOLOGICAL EVALUATION,CRYSTAL-STRUCTURE,GERMAN SITUATION,DESIGNER DRUGS,AMB-FUBINACA,AB-FUBINACA,ADB-PINACA,IN-VITRO,IDENTIFICATION,cannabinoid,indole,indazole,azaindole,NNL-3,HOBt,pharmacology}},
  language     = {{eng}},
  number       = {{21}},
  pages        = {{4020--4036}},
  title        = {{NNL-3 : a synthetic intermediate or a new class of hydroxybenzotriazole esters with cannabinoid receptor activity?}},
  url          = {{http://doi.org/10.1021/acschemneuro.1c00348}},
  volume       = {{12}},
  year         = {{2021}},
}

Altmetric

View in Altmetric

Web of Science

Times cited: